DA
KLRS

Denali Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Denali Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-283
Closed -$22.1K – 552
2023
Q2 		$22.1K Hold
283
– – 0.01% 334
2023
Q1 		$25.6K Hold
283
– – 0.01% 277
2022
Q4 		$33.3K Hold
283
– – 0.01% 267
2022
Q3 		$51K Buy
+283
New +$44.1K 0.02% 208

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Denali Advisors's KLRS Position: Q3 2023 in Review

Denali Advisors sold out of Kalaris Therapeutics (KLRS) in Q3 2023, closing a stake of 283 shares — an estimated $22.1K sold.

Denali Advisors first reported a position in KLRS in Q3 2022 and held it in 4 quarters. The position peaked at $51K in Q3 2022. 90 funds tracked by Wall St. Rank hold KLRS as of Q3 2023.

  • Denali Advisors reported no remaining Kalaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Denali Advisors sold 283 Kalaris Therapeutics shares in Q3 2023, an estimated $22.1K.
  • Denali Advisors first reported a position in Kalaris Therapeutics in Q3 2022 and held it in 4 quarters.
  • Denali Advisors's Kalaris Therapeutics position peaked at $51K in Q3 2022.
  • 90 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2023.

Based on Denali Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.